Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Inspira Technologies Oxy BHN ( (IINN) ) has issued an update.
Inspira Technologies reported full-year 2025 results on March 26, 2026, highlighting progress from clinical validation to early commercialization of its INSPIRA ART100 system, including first patient treatment in April 2025 at Westchester Medical Center and subsequent use in additional leading U.S. hospitals and lung transplant procedures. The company initiated initial commercial deployments, generated $289,000 in 2025 revenue, and secured $49.5 million in binding purchase orders expected to be largely recognized in 2026, while advancing its HYLA blood sensor toward a standalone configuration and reinforcing IP around its ART500 platform.
Strategically, Inspira terminated on March 26, 2026 its previously announced plan to acquire Bio-View Ltd.’s liquid biopsy business, opting instead to review alternative value-creating opportunities. Financially, Inspira posted a 2025 net loss of $13.22 million on operating expenses of $13.62 million, bolstered liquidity with a post-year-end $4.75 million offering and a $4.25 million securities sale, and believes it now meets Nasdaq’s $2.5 million shareholders’ equity requirement for continued listing, a key consideration for investors and partners.
The most recent analyst rating on (IINN) stock is a Sell with a $0.68 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Neutral.
The score is held down primarily by weak financial performance—minimal/erratic revenue, negative gross profit, ongoing net losses, and significant cash burn—implying continued dependence on external funding. Technical indicators are broadly neutral, offering limited offset, while valuation metrics provide little support due to a negative P/E and no dividend yield.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies OXY B.H.N. Ltd. is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures abroad, and underpins development of the next-generation ART500 and the HYLA continuous blood sensor platform, supported by a growing intellectual property portfolio.
Average Trading Volume: 593,502
Technical Sentiment Signal: Sell
Current Market Cap: $23.15M
Find detailed analytics on IINN stock on TipRanks’ Stock Analysis page.